Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
| 52.8 | |
| 49.73 | |
| - | |
| 53.03 | |
| 49.73 | |
| 5.65-65.6 | |
| 2 754 M | |
| 52 165 K | |
| 15 127 K | |
| -0.11 | |
| 3.543 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. Indeed, Janux Therapeutics (NASDAQ:JANX) stock is up 573% in the last...
We recently compiled a list of the 10 Best Hot Stocks To Buy Right Now.In this article, we are going to take a look at where Janux Therapeutics, Inc. (NASDAQ:JANX) stands against the other hot stocks....
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
